Nintedanib drug can benefit patients with broad range of scarring lung diseases

Nintedanib, a medication approved for the treatment of idiopathic pulmonary fibrosis, slows the decline in lung function among patients with a broad range of scarring lung diseases.

From http://besthealthnews.com/2019/09/nintedanib-drug-can-benefit-patients-with-broad-range-of-scarring-lung-diseases/?utm_source=rss&utm_medium=rss&utm_campaign=nintedanib-drug-can-benefit-patients-with-broad-range-of-scarring-lung-diseases

from
https://healthnews010.wordpress.com/2019/09/30/nintedanib-drug-can-benefit-patients-with-broad-range-of-scarring-lung-diseases/